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De novo variants in the gene encoding cyclin-dependent kinase 13 (CDK13) have been 
associated with congenital heart defects and intellectual disability (ID). Here, we present the 
clinical assessment of fifteen individuals and report novel de novo missense variants within 
the kinase domain of CDK13. Furthermore, we describe two nonsense variants and a 
recurrent frame-shift variant. We demonstrate the synthesis of two aberrant CDK13 
transcripts in lymphoblastoid cells from an individual with a splice-site variant. Clinical 
characteristics of the individuals include mild to severe ID, developmental delay, behavioural 
problems, (neonatal) hypotonia and a variety of facial dysmorphism. Congenital heart defects 
were present in two individuals of the current cohort, but in at least 42% of all known 
individuals. An overview of all published cases is provided and does not demonstrate an 
obvious genotype-phenotype correlation, although two individuals harbouring a stop codons 
at the end of the kinase domain might have a milder phenotype. Overall there seems not to 
be a clinically recognizable facial appearance. The variability in the phenotypes impedes an 
à vue diagnosis of this syndrome and therefore genome-wide or gene-panel driven genetic 
testing is needed. Based on this overview we provide suggestions for clinical work-up and 
management of this recently described ID syndrome. 
 
Keywords: CDK13, Congenital Heart Defects, de novo variants, Developmental Delay, 
Facial Dysmorphism, Intellectual Disability, Splice-site variant, Whole-Exome Sequencing 
  










CDK13 (cyclin-dependent kinase 13, OMIM 603309) is a ubiquitously expressed 
serine/threonine kinase. This kinase uses ATP as source of phosphate groups and  forms, in 
conjunction with cyclin K, a protein complex which positively regulates transcription through 
phosphorylation of RNA polymerase II (1). Furthermore, CDK13 is involved in alternative 
splicing of RNA (2, 3) and its mouse homologue regulates axonal elongation (4). 
Recently, de novo missense variants located in the kinase domain of CDK13 have been 
reported (5-8). Sifrim and colleagues describe seven individuals with congenital heart 
defects, mainly of the ventral and atrial septa (6). In addition, these individuals showed 
developmental and motor delay, intellectual disability (ID) and various facial dysmorphisms 
among other features. A further six female individuals with de novo CDK13 variants were 
reported from the Deciphering Developmental Disorders project (7). Common phenotypic 
characteristics of these individuals included ID and dysmorphic facial characteristics. 
Bostwick et al. (5) describe another nine individuals, showing a similar phenotype with 
developmental delay(DD)/ID, congenital heart defects, hypotonia and facial dysmorphisms. It 
is of note that all reported variants in that study are de novo missense variants, with one 
recurrent variant (p.Asn842Ser) reported in seven non-related individuals. Hamilton and 
colleagues (8) provide extensive clinical information on 16 cases, which included an update 
on 13 previously reported individuals (5, 7). 
In the present study, we performed a clinical evaluation of fifteen previously unreported 
individuals with de novo CDK13 variants. Importantly, in addition to novel missense variants, 
we describe for the first time nonsense variants in CDK13. This extended cohort, combined 
with the 25 previously reported individuals, enables us to provide an improved description of 
the syndromic phenotypic spectrum of individuals with de novo variants in CDK13. 
  










Individuals and methods 
Recruitment and examination of individuals with CDK13 variants 
 
Clinical child-parents whole-exome sequencing (trio-WES) at the Department of Human 
Genetics at the Radboudumc (Nijmegen, The Netherlands) (9, 10) resulted in the 
identification of four individuals with de novo variants in CDK13. One individual is a 
monozygotic twin and the same variant was detected in her sister by re-sequencing. Another 
individual was identified by single-case WES. Ten additional individuals with de novo variants 
in CDK13 were recruited based on a ‘genotype-first approach’ via GeneMatcher (11) and had 
undergone clinical exome sequencing in different genetic laboratories in The Netherlands 
and the United States of America. The reference sequence used for CDK13 is RefSeq 
NM_003718.4. All here reported and previously reported variants (Suppl Table 3) are absent 
from the ExAc database (12) as well as the extended version of this database (gnomAD, 
http://gnomad.broadinstitute.org/). All individuals were examined by a clinical geneticist and 
their natural history was reviewed. This study was approved by the institutional review board 
of the Radboud University Medical Center (Commissie Mensgebonden Onderzoek Regio 
Arnhem-Nijmegen NL36191.091.11). Informed consent was obtained for publication of the 




To study the effects of a splice-site variant in intron 7 of CDK13 in mRNA from Individual 10, 
lymphoblastoid cell lines were generated from peripheral blood cells by Epstein-Barr virus 
transformation following standard procedures (13). To check for the occurrence of nonsense-
mediated decay, mRNA was isolated from cells that were cultured in the presence/absence 
of cyclohexamide. CDK13 mRNA was analyzed by the synthesis of cDNA and Sanger 
sequencing according to standard protocols.  












We identified a broad range of CDK13 variants among the fifteen individuals (Table 
1). In addition to missense variants, nonsense variants and a splice-acceptor variant were 
present among this cohort. The variants were shown to have occurred de novo in all but one 
individual; the parents of Individual 13 were not available for testing. The four different 
missense variants, of which three are novel, all lead to changes in the protein kinase domain 
of CDK13 (aa 697-1029), of which two are in (p.Gly714Asp) or close to (p.Arg737Cys) the 
ATP-binding region (aa 711-734) (Fig.1A). The p.Asn842Ser substitution within the kinase-
active site (aa 833-845) (6), was observed in five of the fifteen individuals. Taken together, all 
missense variants affect evolutionary highly conserved regions of CDK13 and were 
anticipated to be deleterious by different prediction algorithms (Supp. Table 2). The two 
nonsense variants (c.2995C>T, p.Arg999* and c.3073C>T, p.Arg1025*) are expected to 
result in a dysfunctional CDK13 by missing one third of the protein. Alternatively, nonsense-
mediated decay of the transcripts might occur leading to a clear reduction in protein level. 
The frame-shift variant c.484dup leading to p.Ala162fs was observed in three independent 
individuals. The consequence of this variant on protein synthesis is not known and might 
involve a lower protein production in the cell because of nonsense-mediated decay of this 
transcript but it is also possible that an alternative translational start site is used. The splice-
acceptor variant c.2601-2A>G detected in the monozygotic twin pair (Individuals 9 and10) 
was predicted to interfere with the correct splicing of intron 7. To test this, we analysed the 
mRNA region downstream of exon 6 from immortalised lymphoblastoid cells derived from 
Individual 9. Three different transcripts were detected (Fig.1B). The correctly spliced mRNA 
was present, supposedly derived from the wild-type CDK13 allele. Another transcript used a 
cryptic splice site in exon 8 leading to an out-of-frame coding sequence. In the third splice 
variant, exons 8 and 9 were missing while the reading frame was conserved in exon 10. The 
mutant transcripts were apparently not affected by nonsense-mediated decay. It is of note 










that all CDK13 variants seem to affect the protein kinase domain and this likely disturbs the 




The majority of the individuals (9 female, 6 male) were examined at a young age (<14 
y), whereas Individuals 5 and 13 were examined at the age of 22 and 54, respectively (Table 
1). Extensive clinical descriptions are given in Supp. Table 1. All individuals displayed DD 
and/or ID (15/15). The degree of ID was variable and varied mostly from mild to moderate, 
although Individual 5 had severe ID. Individual 14 displayed DD and behavioural problems 
but IQ measurement showed a score of 85. Behavioural problems were frequent and 
diverse, and included autism spectrum disorders (5/15), ADHD (4/15) and hyperactivity 
(2/15). Not all individuals underwent cerebral imaging but Individuals 3, 5, 8 were shown to 
have cerebral anomalies on MRI, consisting of focal atrophy of part of the putamen 
(Individual 5), periventricular leukodystrophy (Individual 8) and Chiari malformation 
(Individual 3). Speech problems were commonly reported (7/8) and two individuals had not 
developed speech at their last medical examination at the ages of 8 and 11 years. Feeding 
problems were frequently reported (10/15), mostly as neonate. Notably, in four cases 
(Individuals 2, 7, 11, 13) hyperphagia was reported. Individual 11 had, in addition to the 
CDK13 variant, a paternally inherited frame-shift variant of MC4R, encoding for the 
melanocortin 4 receptor, and variants of this gene are associated with hyperphagia and 
obesity (14), thereby explaining her hyperphagia and overweight. Hypotonia was reported in 
ten individuals. Variable dysmorphic facial features were seen in most individuals (Fig.2) and 
included philtrum abnormalities, blepharophimosis and strabismus. Macrocephaly (>2.5 SD) 
was present in three cases, whereas two individuals showed microcephaly (-2.5 SD) and 
relative short statue (-1.75 SD). The general appearance of some individuals was 
characterized by a hypotonic posture with sloping shoulders (6/14) and flat feet were 
common (9/13). Furthermore, gynaecomastia was seen in three of the six male individuals. It 










is unknown whether the breast tissue was glandular of origin or a benign fat deposit. 
Echocardiography was performed in 9 out of 13 individuals. Two individuals had congenital 
heart defects; Individual 6 had an atrial septum defect and Individual 9 had a patent ductus 
arteriosus. Cardiac screening of Individual 5 showed borderline dilation of the right ventricle 




We evaluated the molecular characteristics and clinical phenotypes of fifteen previously 
unreported individuals with variants in CDK13, of which fourteen were proven de novo, and 
for one individual the parents were not available for testing. A common characteristic and 
interesting observation of the missense variants is that they all cluster in the kinase domain 
of the CDK13 protein, and more specifically, variants cluster mostly in and close to the ATP 
binding site and the active site of the kinase domain. The truncating and splice-site variants 
also affect this kinase domain. The individuals shared several phenotypic characteristics 
including ID/DD with behavioural problems and various facial dysmorphisms. 
 
Spectrum of  reported variants 
In previous publications on individuals with CDK13 variants, only missense (n=24) variants 
and one splice-site variant were reported (5-8) (Suppl. Table 3). Notably, here we describe in 
addition nonsense and frame-shift variants in CDK13. We could not detect a clear genotype-
phenotype correlation although individuals 14 and 15 harboring a stop codon at the end of 
the kinase domain, might show a milder phenotype. Among our group of fifteen individuals, 
the recurrent missense variant leading to p.Asn842Ser substitution was found in five cases. 
Over all the variants that have been reported so far, this is the most frequently encountered 
variant in individuals with the CDK13 syndrome (17/40, 43%). Interestingly, both Bostwick et 
al. (5) and Hamilton et al. (8) report another variant at this amino acid position (c.2525A>G, 










p.Asn842Asp) which introduces a negative charge in the active site of the protein kinase 
domain. The variants leading to p.Arg737Cys and p.Arg880Cys were not reported before and 
locate in the kinase domain as all other reported missense variants do. The marked 
reduction in the genetic variation in the kinase domain of CDK13 in comparison with other 
regions of the protein among healthy individuals (12), indeed suggests that little variation is 
tolerated within the kinase domain. Furthermore, Hamilton et al. (8) performed in silico 
protein modelling to investigate the effect of the variants on CDK13 structure and to gain 
insight into the possible molecular basis of pathogenicity. The authors presume a dominant 
negative mechanism, although this is not substantiated by functional studies. In this study, 
we report three unrelated individuals with an identical frame-shift variant (c.484dup, 
p.Ala162fs) and we describe two individuals with non-sense variants located at the C-
terminal end of the kinase domain. Importantly, these individuals with the frame-shift and 
nonsense variants were clinically indistinguishable from those carrying missense variants in 
the kinase region of CDK13 (Supp. Table 1 and Fig. 2).  
 
Mechanistic models 
This observation might suggest that there is a similar mode of action between the two groups 
of genetic variants, and a haploinsufficency model might explain that we could not observe a 
genotype-phenotype correlation. However, currently it is still feasible that (some of) the 
missense mutations located in the CDK13 kinase domain have a dominant negative effect.  
Functional experiments might provide deeper insight into the precise molecular mechanisms 
of the various de novo variants in CKD13. The here reported frame-shift and non-sense 
variants are as well expected to result in haploinsufficiency of the CDK13 gene. In addition, 
copy-number losses including the entire CDK13 gene are strikingly absent from the 
Database of Genomic Variants (15), which supports a haploinsufficiency mode of action. It is 
noted that the gnomAD database (November, 2017) contains nine high-confidence non-
sense variants and two frame-shift variants (of which one is present twice). The gnomAD 
database does not include individuals with severe paediatric disease, but mild phenotypes 










might be included. It would be of interest to explore the medical history of the concerned 
individuals. Therefore, based on our current data, we hypothesize that the missense variants 
in the kinase domain of CDK13 lead to a structural and/or functional deformation of the 
kinase domain of CDK13 and abrogate its catalytic function. 
 
Clinical spectrum and suggestions for clinical practise 
In Table 1, we present an overview of the main clinical features of the individuals described 
in this study and those reported previously (5-8). In total 27 female and 13 male individuals 
are reviewed. As previously mentioned, there is no obvious correlation between specific 
gene variants and a specific clinical phenotype. Our study does therefore not support a clear 
genotype-phenotype correlation. ID/DD is present in all individuals and is mostly 
accompanied by a variety of behavioural problems, although not all studies report on 
behavioural aspects. The frequency of structural brain anomalies varied between the 
different reports. Cerebral imaging was not performed in all individuals. Hypotonia is 
observed in more than 75% of the individuals, mostly at the neonatal stage. Post-neonatal 
hypotonia is possibly reflected by the high incidence of pes planus (9/13) and sloping 
shoulders (in present study, 43%). A variety of facial dysmorphisms are frequently seen in 
the individuals, with thin lips, eye lid abnormalities and a broad nose/nasal bridge as the 
most frequently reported features. Stratification of the individuals according to their genetic 
variants did not reveal consistency of the facial appearance per variant (Table 2). Sifrim and 
colleagues selected for individuals with congenital heart defects (1,891 individuals) and 
identified among their cohort seven individuals with de novo variants in CDK13 (6). All these 
individuals had septal defects. In the other studies, congenital heart defects were observed 
as well (over all studies16/38 (42%), Table 2). We suggest echocardiography for individuals 
with newly discovered CDK13 variants in the clinical work-up. Because most of the 
investigated individuals are young children (below the age of fourteen), we recommend to 
closely monitor the currently identified group of individuals to improve description of the 
natural course of this syndrome. The identification of individuals with this CDK13 syndrome 










has meanwhile resulted in the formation of parent groups on social media, an important 
social aspect of current research. We conclude that individuals with de novo CDK13 variants 
do show a syndromic intellectual disability phenotype, with facial dysmorphisms, congenital 
heart defects, hypotonia and behavioural problems as the most frequent features. Previous 
studies (5, 8) reported a recognisable facial gestalt among their individuals with CDK13 
variants. Our study confirms the presence of dysmorphic facial features in all individuals, 
although the facial phenotype might not be specific nor consistent enough to enable à vue 
clinical diagnosis. Also, with the increasing number of individuals described, the clinical 
variation seems to divert further. To further delineate the clinical spectrum associated with de 
novo variants of CDK13 we established a website to collect detailed clinical information of 
additional individuals that will be identified over the coming years 
(www.humandiseasegenes.com). Based on the current clinical findings of all reported cases, 
we provide the following suggestions for clinical work-up and management. Early 
assessment should include, cardiac and neurologic evaluation with special attention for 
increased seizure risk. The high incidence of hypotonia and neonatal feeding problems 
requires special attention, close monitoring enabling early intervention to support feeding if 
needed. Language delay requires proactive speech therapy. As clinical recognition of the 
CDK13 syndrome will be challenging, a genotype-first approach, by either WES or ID gene 
panel analysis (including CDK13), will be crucial in diagnosing this new syndrome. 
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Figure legends  
 
Fig. 1. Localisation of the amino-acid (aa) residue substitutions in the CDK13 protein of all 
presently reported and published individuals (5-8), and transcript analysis of a splice-site 
mutation in CDK13. (a) Schematic localisation of all presently and earlier reported de novo 
CDK13 variants. The variants reported in this study are shown above the protein in red and 
those reported in earlier studies are depicted below the protein in blue. Numbering of aa is 
based on the wild-type transcript NM_003718.4. The indicated functional domains of the 
protein are derived from Kohoutek and Blazek, 2012 (16). (b) Overview of the various 
transcripts detected in lymphoblastoid cells derived from Individual 9 with the c.2601-2A>G 
splice-acceptor variant. The wild-type transcript is presumably from the unaffected allele, 
whereas two other transcripts are a consequence of the splice-acceptor variant. In the first 
transcript, a cryptic splice-acceptor site is used at position c.2620, whereas in the second 
one, exons 8 and 9 are skipped and in exon 10 the wild-type open-reading frame is used, 
which leads to the deletion of 60 aa’s in the kinase domain of the encoded protein. 
 
  
Fig. 2. Facial features of individuals with de novo variants in CDK13 presented in this study.  
 
Supporting information 
Supplementary Table 1. Clinical features of individuals with variants in CDK13. 
Supplementary Table 2. Location and conservation of missense variants in CDK13. 
Supplementary Table 3. Reported CDK13 variants associated with Developmental Delay 
and/or Intellectual Disability. 
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Individual 1 2 3 4 5 6 7 8 9‡ 10‡ 11 12 13 14 15 Cumulative
Gender M F F F M F F M F F F M M M F 9 F,  6 M
Age at examination 6 y, 3 m 8 y 9 y 10 y, 1 m 22 y 11 y 13 y 9 y , 10 m 13 y 13 y 11 y 13 y 54 y 9 y 3 y, 4 m






























ID/DD + (moderate ID) + (moderate ID) - (borderline ID) + (mild ID) + (moderate ID) + (moderate ID) + (DD/ID) + (borderline ID) + (mild ID) + (mild ID) + (mild ID) + (moderate ID) + (mild ID) + (borderline ID) + (DD)
 15/15
Feeding problems + + + - + - + + - + + + + (as child) - - 10/15
Head circumference (SD) +1 SD -1 SD + 1 SD + 0.75 SD +0.39 SD > 2.5 SD + 1 SD 0 SD < -2.5 SD < -2.5 SD > 2.5 SD + 0.7 SD +0.5 SD + 3 SD +1.53 SD 3/15 macrocephaly; 2/15 microcephaly
Behavioural problems  + + + + + +  + + + + + + + + + 15/15
Hypotonia + + + + + NR + + + + - + NR - NR 10/12
Speech problems + + + - + + NR NR NR NR NR + NR NR + 7/8
Sleeping problems - - + - + (until 12 y) NR - + - - NR + - + - 5/13
Congenital malformations
Congenital heart defects - - - - - + - - + NR - - NR - - 2/13
Structural brain abnormalities NR - + NR + NR - + NR NR NR - NR NR - 3/7
Facial
Flat midface + - - + + - - + - - + - + - - 6/15
Blepharophimosis + - - - + + - + - + -  + + - - 7/15
Hypertelorism + - - - + + - + - - + - + - - 6/15
Eye anomalies (strabismus) - + + + + - + + - + + - + + - 10/15
Ear abnormalities + + + + + - - - - - - - + + - 7/15
Broad nose/nasal bridge + + +  + + - - - + + + + + -  + 11/15
Philtrum abnormalities + -  + - + - - -  + +  + - + +  + 9/15
Thin lips (narrow mouth) - - +  + - - - - + + - + - + + 7/15
Small mouth + - + + - + - - - - - - - - - 4/15
Others
Sloping shoulders + - + + + NR - + + + - - - - - 6/14
Gynaecomastia (males) - NA NA NA + NA NA + NA NA NA - - + NA 3/5
Joint pathology + - + + + NR + NR + - NR - NR NR - 6/10
Pes planus - - + - + NR + + + + - + NR + + 9/13
†Extensive clinical data are given in Suppl Table 1
Table 1.  Summary of major clinical features of individuals with variants in CDK13 †
Abbreviations are as follows: F, female; M, male; y, year; m, month; +, present; -, absent; NR, not reported; NA, not applicable
‡Monozygotic twins










Study Sifrim et al ., 2016 DDD Study, 2017 Bostwick et al ., 2017 Hamilton et al ., 2017 Current study
Number of described individuals 7 13 16 16 15
Number of novel individuals‡ 5 F, 2 M 6 F 4 F,  5 M 3 F 9 F,  6 M
Neurological and behaviour
ID/DD 7/7 6/6 9/9 3/3 15/15 40/40 (100%)
Feeding problems 7/7 5/6 NR 3/3 10/15 18/31 (58%)
Microcephaly 4/7 1/6 1/8 1/3 2/15                                       9/25 (36%)
Macrocephaly 0/7 0/7 0/8 0/7 3/15 3/25 (12%)
Behavioural problems 3/3 4/4 NR 1/1 15/15 23/23 (100%)
Hypotonia 3/7 2/4 9/9 1/2 10/12 25/34 (75%)
Speech problems 7/7 NR 9/9 NR 7/8 23/24 (96%)
Sleeping problems 2/2 1/1 NR NR 5/13 8/16 (50%)
Congenital malformations
Congenital heart defects 7/7 0/6 6/9 1/3 2/13 16/38 (42%)
Structural brain abnormalities 4/6 1/5 5/6 1/1 3/7 19/25 (76%)
Facial
Flat midface NR 1/1 NR NR 6/15 7/16 (44%)
Blepharophimosis 2/5 6/6 NR 1/3 7/15 16/29 (55%)
Hypertelorism 4/7 2/6 6/8 1/3 6/15 19/39 (49%)
Eye anomalies 4/7 4/6 6/9 1/3 10/15 25/40 (63%)
Ear abnormalities 4/7 5/6 8/9 2/3 7/15 27/40 (68%)
Broad nose/nasal bridge 5/7 4/6 6/8 2/3 11/15 28/39 (72%)
Philtrum abnormalities 3/7 3/6 NR 0/3 9/15 15/31 (48%)
Thin lips (narrow mouth) 6/7 4/6 5/8 2/3 7/15 24/39 (62%)
Others
Sloping shoulders NR NR NR NR 6/14 6/14 (43%)
Gynaecomastia (males) NR NR NR NR 3/5 3/5 (60%)
Joint pathology 1/7 1/6 NR 1/3 6/10 9/26 (35%)
Pes planus NR NR NR 1/3 9/13 10/16 (63%)
†An overview of all reported individuals is given in Suppl Table 3.
‡Since some individuals have been reported multiple times over different reports, only the firstly published study is indicated here.
  Clinical information from later published studies on certain individuals is included in this overview.
Table 2.  Overview of main clinical features of individuals with variants in CDK13 †
27 F, 13 M
Cumulative
Abbreviations are as follows: F, female; M, male; ; NR, not reported
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